Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus
ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous
squamous cell carcinoma.